We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

69 hedge funds and large institutions have $94.1M invested in Aevi Genomic Medicine Inc in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

650% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 2

73% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 15

59% more capital invested

Capital invested by funds: $59.4M → $94.1M (+$34.8M)

23% more funds holding

Funds holding: 56 → 69 (+13)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
69
Holders Change
+13
Holders Change %
+23.21%
% of All Funds
1.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
26
Reduced
15
Closed
2
Calls
$99K
Puts
–
Net Calls
+$99K
Net Calls Change
+$99K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.46M
2
SFM
Sphera Funds Management
Israel
+$2.36M
3
OM
Opaleye Management
Massachusetts
+$2.06M
4
BC
Broadfin Capital
New York
+$1.71M
5
PA
Perceptive Advisors
New York
+$1.58M

Top Sellers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
-$239K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$193K
3
AA
ALPS Advisors
Colorado
-$163K
4
QF
QVT Financial
New York
-$98.8K
5
Citigroup
Citigroup
New York
-$96.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$18.7M +$1.71M +325,000 +11%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$11.7M +$4.46M +850,000 +68%
OM
3
Opaleye Management
Massachusetts
$10.8M +$2.06M +392,300 +25%
Jennison Associates
4
Jennison Associates
New York
$9.74M -$31.6K -6,009 -0.3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.37M +$792K +150,885 +18%
BBA
6
Baker Bros. Advisors
New York
$4.89M +$607K +115,539 +15%
QF
7
QVT Financial
New York
$4.56M -$98.8K -18,808 -2%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$4.22M -$20K -3,800 -0.5%
BFA
9
BlackRock Fund Advisors
California
$3.51M +$359K +68,454 +12%
BIT
10
BlackRock Institutional Trust
California
$3.47M +$197K +37,434 +6%
SFM
11
Sphera Funds Management
Israel
$2.5M +$2.36M +450,000 New
PA
12
Perceptive Advisors
New York
$1.67M +$1.58M +300,000 New
State Street
13
State Street
Massachusetts
$1.63M +$190K +36,152 +14%
Northern Trust
14
Northern Trust
Illinois
$1.53M +$148K +28,155 +11%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.08M +$80.7K +15,367 +9%
BCM
16
Bridgeway Capital Management
Texas
$874K +$202K +38,500 +32%
SM
17
Sabby Management
Florida
$770K +$729K +138,777 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$572K +$41.6K +7,931 +8%
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$555K +$525K +100,000 New
BIM
20
BlackRock Investment Management
Delaware
$496K +$109K +20,843 +30%
CC
21
Casdin Capital
New York
$472K +$446K +85,000 New
TCIM
22
TIAA CREF Investment Management
New York
$450K +$101K +19,246 +31%
Tudor Investment Corp
23
Tudor Investment Corp
Connecticut
$444K +$420K +80,000 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$284K +$19.7K +3,746 +8%
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$283K – – –
1
2 3

GNMX Hedge Fund Activity: Q2 2016 in Review

69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2016, worth a combined $94.1M — up 59% from $59.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GNMX positions and 2 closed out — a net gain of 13 holders — while 26 added to existing stakes and 15 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.46M. The largest seller was LPL Financial, cutting an estimated $239K.

  • 69 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2016, up from 56 in Q1 2016.
  • Funds reported $94.1M of Aevi Genomic Medicine Inc stock for Q2 2016, up 59% quarter-over-quarter.
  • 15 funds opened new Aevi Genomic Medicine Inc positions in Q2 2016 and 2 closed out, a net change of +13 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q2 2016 was Adage Capital Partners, an estimated $4.46M added.
  • The largest Aevi Genomic Medicine Inc seller in Q2 2016 was LPL Financial, an estimated $239K sold.

Based on aggregated 13F filings for Q2 2016.